Method of Treating or Preventing Oxidative Stress-related Diseases (stroke and neurodegenerative diseases, wound healing and cardiovascular diseases)
Description of Invention:
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) produce oxidative stress to DNA, lipids and proteins thus causing cellular and tissue damage. A number of diseases are associated with oxidative stress including Alzheimer's disease, ischemic stroke, heart disease, cancer, hepatitis, and autoimmune disease. Uric acid is a natural antioxidant effective in reducing ROS and research has shown that uric acid contributes approximately two-thirds of all free radical scavenging capacity in plasma. Because uric oxide is too insoluble to be used as a therapeutic agent, scientists at the NIH developed uric acid analogs with improved anti-oxidative and solubility properties for use as free radical scavengers or antioxidants. These analogs increased survival of PC12 and hippocampal neurons after challenge by Fe, MPP and Glutamate. When administered to a mouse model of focal ischemic stroke, these compounds protect neuronal cells from ROS and reduce brain damage and ameliorate neurological deficits. Other studies show a single application of these analogs on skin lacerations in mice decreased the time for wound repair. Available for licensing are methods of treating ischemic stroke and wound healing, and for the prevention or treatment of other oxidative stress-related diseases, such as epilepsy, Parkinson's disease and dementia.
Applications:
Novel uric acid analogs for use as antioxidants to help reduce the risk of stroke, neurological diseases and assisting with wound repair.
Market:
Stroke is the third-leading cause of death and the leading cause of severe neurological disability worldwide.
Americans will pay approximately $62.7 billion dollars in 2007 for stroke-related medical costs and disability.
Patent Status:
DHHS Reference No. E-059-2006/0 --
U.S. Provisional Application No. 60/839,800 filed 23 Aug 2006
PCT Application No. PCT/US2007/076597 filed 23 Aug 2007, which published as WO 2008/024893 on 28 Feb 2008
Licensing Status: Available for licensing.
Collaborative Research Opportunity:
The National Institute on Aging, Laboratory of Neurosciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the described uric acid analogue technology in the treatment of neurodegenerative diseases, wound healing and cardiovascular disease. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Internal Medicine Central Nervous System
Central Nervous System -Therapeutics-Neurological Therapeutics-Antiparkinsonian Central Nervous System -Therapeutics-Neurological Therapeutics-Alzheimer Central Nervous System -Therapeutics-Neurological Therapeutics-Stroke Central Nervous System -Therapeutics Internal Medicine-Therapeutics
For Additional Information Please Contact: Norbert J. Pontzer PhD JD
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5502
Email: pontzern@mail.nih.gov
Fax: (301) 402-0220
